$4.05 12.2%
ME Stock Price vs. AI Score
Data gathered: December 7

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - 23andMe (ME)

Analysis generated November 21, 2024. Powered by Chat GPT.

23andMe, headquartered in Sunnyvale, California, is a genomics and biotechnology company primarily known for offering direct-to-consumer genetic testing services. Founded in 2006, the company has become a significant player in personalized health and ancestry information via genetic data. Their model empowers consumers with access to their genetic information, promoting greater health awareness and fostering interest in ancestry-related information.

Read full AI stock Analysis

Stock Alerts - 23andMe (ME)

company logo 23andMe | December 6
Price is up by 6.7% in the last 24h.
company logo 23andMe | December 5
Price is up by 5.6% in the last 24h.
company logo 23andMe | December 3
Price is up by 6% in the last 24h.
company logo 23andMe | December 3
Business Outlook among employees is up by 30.8% over the last month.

About 23andMe

23andMe Holding Co. is a publicly held personal genomics and biotechnology company based in South San Francisco, California.


23andMe
Price $4.05
Target Price Sign up
Volume 508,570
Market Cap $94M
Year Range $2.83 - $12.22
Dividend Yield 0%
Analyst Rating 0% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2444M22M22M-59M-57M-46.320
Q2 '2440M20M21M-69M-68M-0.120
Q1 '2464M37M27M-209M-208M-0.110
Q4 '2345M25M20M-278M-276M-0.160
Q3 '2350M28M22M-75M-72M-0.160

Insider Transactions View All

HIBBS KATHY L filed to sell 1,252,315 shares at $0.5.
May 6 '24
HIBBS KATHY L filed to sell 1,252,315 shares at $0.5.
April 19 '24
HIBBS KATHY L filed to sell 1,252,315 shares at $0.5.
April 5 '24
HIBBS KATHY L filed to sell 1,252,315 shares at $0.5.
March 22 '24
HIBBS KATHY L filed to sell 1,252,315 shares at $0.5.
March 11 '24

What is the Market Cap of 23andMe?

The Market Cap of 23andMe is $94M.

What is the current stock price of 23andMe?

Currently, the price of one share of 23andMe stock is $4.05.

How can I analyze the ME stock price chart for investment decisions?

The ME stock price chart above provides a comprehensive visual representation of 23andMe's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling 23andMe shares. Our platform offers an up-to-date ME stock price chart, along with technical data analysis and alternative data insights.

Does ME offer dividends to its shareholders?

As of our latest update, 23andMe (ME) does not offer dividends to its shareholders. Investors interested in 23andMe should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of 23andMe?

Some of the similar stocks of 23andMe are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.